00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
01:11 , Jul 15, 2017 |  BC Extra  |  Company News

Management tracks

Immunotherapy company Advaxis Inc. (NASDAQ:ADXS) said President and CEO Daniel O’Connor resigned. CBO Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB (Stockholm, Sweden) named Matthew Gantz...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
18:35 , Jul 6, 2017 |  BC Week In Review  |  Financial News

Avenue raises $33M in IPO

Neurology company Avenue Therapeutics Inc. (NASDAQ:ATXI) raised $33 million through the sale of 5.5 million shares at $6 in an IPO underwritten by Oppenheimer and the National Securities Corp. subsidiary of National Holdings Inc. (NASDAQ:NHLD)...
19:22 , Jun 27, 2017 |  BC Extra  |  Financial News

Avenue rises after $33M listing

Avenue Therapeutics Inc. (NASDAQ:ATXI) gained $2.25 (38%) to $8.25 in its first day of trading Tuesday afternoon after it raised $33 million through the sale of 5.5 million shares at $6 in an IPO underwritten...
00:27 , May 3, 2017 |  BC Week In Review  |  Financial News

Avenue proposes IPO

On May 1, neurology company Avenue Therapeutics Inc. (New York, N.Y.) proposed to raise up to $50 million in an IPO underwritten by Raymond James and the National Securities Corp. Avenue Therapeutics Inc. , New...